Effect of HMG-CoA Reductase Inhibition on Vascular Smooth Muscle Cells Extracellular Matrix Production: Role of RhoA

被引:6
|
作者
Palomino-Morales, Rogelio [1 ]
Perales, Sonia [1 ]
Torres, Carolina [1 ]
Linares, Ana [1 ]
Alejandre, Maria J. [1 ]
机构
[1] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, Fuentenueva S-N, E-18071 Granada, Spain
关键词
Extracellular matrix; Collagen type I; III; fibronectin; gene expression; smooth muscle cells; RhoA; lovastatin; mevalonate; geranylgeranyl pyrophosphate; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; MEVALONATE PATHWAY; IN-VITRO; COLLAGEN; FIBRONECTIN; STATINS; GROWTH; CHOLESTEROL; EXPRESSION; ATHEROSCLEROSIS;
D O I
10.2174/1570161114666160229115553
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cholesterol-lowering effects apart, statins can improve the endothelial function, stabilize the atherosclerotic plaques, decrease the oxidative stress and inflammation and inhibit the thrombogenic response by means of the inhibition of isoprenoids, which serve as lipid attachments for intracellular signaling molecules. We aimed to evaluate whether the effect of statins on RhoA activity mediate extracellular matrix production, particularly affecting collagen type I, in smooth muscle cells (SMCs). Our results showed that lovastatin decreased collagen expression in primary cultured chicken SMCs as determined by incorporation of [H-3]-proline, RT-PCR and immunocytochemistry. This fall was parallel to that found in Rho A activity. Similar results were found when GGTI-298, a RhoA inhibitor, was added to the culture medium. Mevalonate or geranylgeranyl pyrophosphate reverted these effects. In order to elucidate the role of Rho A in these events we transfected the cell line A10 (rat SMCs) with constitutively active (G14V) or dominant negative RhoA (T19N) constructs. The last ones showed similar results regarding collagen production that those stated above in lovastatin treated primary SMC cultures. Constitutively active RhoA transfected cells showed the opposite effects. Next we performed a promoter activity assay to exclude post-transcriptional mechanisms implicated in these studies. We found a similar pattern in col1a2 promoter activity to that found in collagen expression. Our results have demonstrated that statins regulate the activation of RhoA through its isoprenylation, which is crucial for the regulation of extracellular matrix synthesis in SMCs.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 50 条
  • [1] Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells
    Riessen, R
    Axel, DI
    Fenchel, M
    Herzog, UU
    Rossmann, H
    Karsch, KR
    BASIC RESEARCH IN CARDIOLOGY, 1999, 94 (05) : 322 - 332
  • [2] Extracellular matrix effect on RhoA signaling modulation in vascular smooth muscle cells
    Lim, Soon-Mi
    Kreipe, Bryan A.
    Trzeciakowski, Jerome
    Dangott, Larry
    Trache, Andreea
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (17) : 2833 - 2848
  • [3] Inhibition of extracellular matrix production and remodeling by doxycycline in smooth muscle cells
    Palomino-Morales, Rogelio
    Torres, Carolina
    Perales, Sonia
    Linares, Ana
    Jose Alejandre, Maria
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 132 (04) : 218 - 223
  • [4] Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental?
    Katsiki, Niki
    Tziomalos, Konstantinos
    Chatzizisis, Yiannis
    Elisaf, Moses
    Hatzitolios, Apostolos I.
    ATHEROSCLEROSIS, 2010, 211 (01) : 9 - 14
  • [5] HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells
    Erl, W
    Hristov, M
    Neureuter, M
    Yan, ZQ
    Hansson, GK
    Weber, PC
    ATHEROSCLEROSIS, 2003, 169 (02) : 251 - 258
  • [6] HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells
    Ito, T
    Ikeda, U
    Shimpo, M
    Ohki, R
    Takahashi, M
    Yamamoto, K
    Shimada, K
    CARDIOVASCULAR DRUGS AND THERAPY, 2002, 16 (02) : 121 - 126
  • [7] HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells
    Dichtl, W
    Dulak, J
    Frick, M
    Alber, HF
    Schwarzacher, SP
    Ares, MPS
    Nilsson, J
    Pachinger, O
    Weidinger, F
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) : 58 - 63
  • [8] Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells
    Ito, T
    Ikeda, U
    Yamamoto, K
    Shimada, K
    ATHEROSCLEROSIS, 2002, 165 (01) : 51 - 55
  • [9] HMG-CoA Reductase Inhibitors Reduce Interleukin-6 Synthesis in Human Vascular Smooth Muscle Cells
    Takayuki Ito
    Uichi Ikeda
    Masahisa Shimpo
    Ruri Ohki
    Masafumi Takahashi
    Keiji Yamamoto
    Kazuyuki Shimada
    Cardiovascular Drugs and Therapy, 2002, 16 : 121 - 126
  • [10] The effects of HMG-CoA reductase inhibitor on vascular progenitor cells
    Kusuyama, Takanori
    Omura, Takashi
    Nishiya, Daisuke
    Enomoto, Soichiro
    Matsumoto, Ryo
    Murata, Takashi
    Takeuchi, Kazuhide
    Yoshikawa, Junichi
    Yoshiyama, Minoru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 (04) : 344 - 349